Cerebral Sinus Thrombosis in a Patient with Humoral Immunodeficiency on Intravenous Immunoglobulin Therapy: A Case Report

Abstract

We present the case of an 11-year-old boy with humoral immunodeficiency on monthly intravenous immunoglobulins (IVIG) infusions, evaluated for recurrent, brief, neurological deficits secondary to cerebral sinus thrombosis without any identifiable hypercoagulability state. Etiologic possibilities for the thrombotic event are presented with special discussion of IVIG-related cerebral thrombosis. To the best of our knowledge, our patient represents the first reported case of Bruton's disease on IVIG therapy developing a cerebral ischemic event and the second reported case of cerebral sinus thrombosis associated with IVIG use for any disease. Potential concerns regarding the risk of cerebral thrombosis during IVIG therapy in this and other disorders are reviewed.

Key words

dural sinus thrombosis - intravenous immunoglobulins - Bruton's disease

References

• 1 Alper F, Kantarci M, Dane S, Gumustekin K, Onbas O, Durur I. Importance of anatomical asymmetries of transverse sinuses: an MR venographic study.  Cerebrovasc Dis. 2004;  18 236-239
• 2 Caress JB, Cartwright MS, Donofrio PD, Peacock Jr JE. The clinical features of 16 cases of stroke associated with administration of IVIG.  Neurology. 2003;  60 1822-1824
• 3 Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events.  Neurology. 1994;  44 223-226
• 4 Dalakas MC, Clark WM. Strokes, thromboembolic events, and IVIG, Rare incidents blemish an excellent safety record.  Neurology. 2003;  60 1736-1737
• 5 Evangelou N, Littlewood T, Anslow P, Chapel H. Transverse sinus thrombosis and IVIG treatment: a case report and discussion of risk-benefit assessment for immunoglobulin treatment.  J Clin Pathol. 2003;  56 308-309
• 6 FDA . Interim statement regarding immune globulin intravenous (IGIV). , August 27, 2002: http://www.fda.gov/cber/infosheets/IVIG082702.htm
• 7 Hefer D, Jaloudi M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature.  Ann Hematol. 2004;  83 661-665
• 8 Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.  N Engl J Med. 2001;  345 747-755
• 9 Zaidan R, Al Moallem M, Wani BA, Shameena AR, Al Tahan AR, Daif AK. Thrombosis complicating high-dose intravenous immunoglobulin: report of three cases and review of the literature.  Eur J Neurol. 2003;  10 367-372
• 10 Wada Y, Kamei A, Fujii Y, Ishikawa K, Chida S. Cerebral infarction after high-dose intravenous immunoglobulin therapy for Kawasaki disease.  J Pediatr. 2006;  148 399-400
• 11 Wolberg AS, Kon RH, Monroe DM, Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations.  Am J Hematol. 2000;  65 30-34

Correspondence